Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Organon & (OGN)

Organon to be acquired by Sun Pharma for $14.00 per share in cash

Positive Impact 5 of 5 m&a Written later

Organon agreed on April 26, 2026 to be acquired by Sun Pharma entities in an all-cash merger valued at an enterprise value of $11.75 billion. The $14.00 per share price represents a 103% premium to the closing share price on April 9, 2026, and the deal requires Organon stockholder approval and regulatory clearances.

Key points

  • Organon stockholders would receive $14.00 per share in cash, a 103% premium to the April 9, 2026 closing price
  • Enterprise value of the deal is $11.75 billion; Sun Pharma plans to fund it with available cash and committed bank financing
  • The transaction is expected to close in early 2027 and can be terminated if the merger is not completed by January 26, 2027
  • If completed, Organon shares would be delisted from the New York Stock Exchange

The filing

CompanyOrganon & (OGN)
Form8-K, current report
Filed with the SECApr 27, 2026, 6:06 AM ET
Accession number0001193125-26-178718

Items reported: 1.01 Material Definitive Agreement5.02 Director / Officer Change7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:38 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on April 27, 2026.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.